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THE ROLE OF INTRAOPERATIVE PARATHYROID HORMONE
MONITORING FOR PARATHYROID HYPERPLASIA
Misra S,Weber KJ,Wilhelm SM, Prinz RA
Rush University Medical Center, Chicago, IL, USA
OBJECTIVE: Utility of intra-operative parathyroid hormone
(IOPTH) monitoring in parathyroidectomy for multi-glandular
disease is less clear than for single gland disease. This study
assesses the role of IOPTH monitoring during surgery for
parathyroid hyperplasia. METHODS: From February 1999 to
June 2003, 273 patients with hyperparathyroidism underwent
parathyroidectomy utilizing IOPTH by a single surgeon. A
prospective database revealed 44 patients with parathyroid
hyperplasia. Baseline serum intact parathyroid hormone levels
were drawn at initial placement of the intravenous catheter for
anesthesia. Additional levels were drawn from the ipsilateral
internal jugular vein after exposure of the parathyroid glands.
Post-excision values were drawn at 5 and 10 minutes after the
completion of parathyroidectomy. Additional values were drawn
as needed to conﬁrm an appropriate drop in IOPTH levels.
IOPTH levels were compared and evaluated statistically using
SPSS software. RESULTS: Twenty-one patients with end stage
renal disease and ﬁve patients with multiple endocrine neoplasia
I underwent total parathyroidectomy. The remaining 18 patients
underwent subtotal parathyroidectomy. A drop in IOPTH to 35
pg/ml or to 90% of the baseline value was predictive of a suc-
cessful operation in 39 patients. Five patients failed to meet these
criteria. The mean ﬁnal IOPTH levels in the 39 patients was 
44.4pg/ml compared to 345.2pg/ml in the 5 patients (Mann-
Whitney Test, p < 0.003). Of the ﬁve failed patients, three were
found to have ectopic parathyroid tissue in the mediastinum and
two were lost to follow up. CONCLUSION: IOPTH levels can
identify patients with sporadic hyperplasia and can guide com-
pleteness of resection for patients with known hyperplasia.
However more rigid criteria are required than for adenomas.
Failure to achieve appropriate decreases in IOPTH should
prompt further neck exploration or a search for a mediastinal
gland.
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POTENTIAL MEDICAL COST REDUCTION DUE TO
DECREASES IN A1C RESULTING FROM PHARMACIST
DIABETES EDUCATON AND MEDICATION
RECOMMENDATIONS IN A COMMUNITY SETTING
Gunderson SM, Lee KY, Duvel AH, Luce DF
Walgreens Health Initiatives, Deerﬁeld, IL, USA
OBJECTIVES: Research indicates that decreases in A1C from
9% to 8% reduce health-care cost differentials by $1101 per dia-
betic and $1597 per hypertensive-diabetic over a 3-year period.
To combat diabetes and its related health care costs, a pharma-
cist-driven community-based diabetes care program was imple-
mented in southern Texas. Both clinical and economic outcomes
from this program are presented. METHODS: Patients with
type-2 diabetes were referred to this program. Patients scheduled
one to three visits, based on clinical parameters, with specially-
trained pharmacists and received education, glucose-meter train-
ing and onsite laboratory testing. Data including demographics,
laboratory, medical, social history and pharmacist medication
recommendations were entered into a relational database
(Microsoft Access®). Differential cost and annual medical 
inﬂation rate were obtained from the literature. Program effec-
tiveness was evaluated using a random coefﬁcient model for con-
tinuous and GEE for binary outcomes. RESULTS: A total of
1795 patients were seen at ﬁrst visit. 827 (46%) completed a
second, and 389 (22%) completed a third visit. Of those who
completed 3 visits, 369 (95%) continued to receive monitoring
of A1C levels. Eighty percent of patients (297 of 369) received
pharmacist education alone and had a signiﬁcantly reduced
average A1C from 7.37% to 7.08% (p < 0.0001) from visit one
to three. Twenty percent of the patients (72 of 369) received
pharmacist diabetes education and medication recommendations
and had reduced average A1C levels, 8.95% to 7.98% (p <
0.0001) from visit one to three. Of the 72 patients, 47% were
hypertensive-diabetics (systolic blood pressure >140 or diastolic
blood pressure >90). Among the 34 hypertensive-diabetics and
38 non-hypertensive-diabetics, potential per-patient medical cost
savings based on A1C reduction, averaged $1280 ($92,149),
over a 3-year period. CONCLUSIONS: Pharmacist diabetes 
education and medication recommendations performed in a
community setting signiﬁcantly decreased A1C in type-2 
diabetics resulting in a potential reduction in health care costs of
$1280 per-patient, over 3 years.
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UTILIZATION PATTERNS OF DRUGS AND HEALTH CARE
SERVICES AMONG RECIPIENTS WITH DIABETES IN A
MEDICAID POPULATION
Sundaram M, Smith MJ
West Virginia University, Morgantown, WV, USA
Diabetes is the 7th leading chronic disease in the United States,
and is responsible for substantial consumption of medical
resources. Few studies have examined the distribution of the
disease among patients of lower socioeconomic groups. OBJEC-
TIVE: To report patterns of drug and health care utilization
among people with diabetes who received Medicaid beneﬁts.
METHODS: Medicaid administrative claims for medical services
with a primary ICD-9 code for diabetes dated during calendar
year 2002 were extracted. Claims for recipients younger than 65
years of age were used for the analysis. From these claims, unique
and anonymous recipient codes were collected and then used 
to extract prescription claims for diabetes-related medications.
Reported costs were from the perspective of Medicaid.
RESULTS: There were 14,306 recipients identiﬁed with diabetes.
Among gender, ethnic, and age groups, a majority of recipients
were female (63%), white (93%), and between 21 and 64 years
of age (96%). The rate of diabetes was 40 per 1000 recipients.
Medical services were consumed at a rate of 174 outpatient visits
per 1000 recipients, 39 emergency department (ED) visits per
10,000 recipients, and 26 hospital admissions per 10,000 recip-
ients. Costs for medical services totaled nearly $8 million, a
majority of which was for outpatient services (51%). Medicaid
paid approximately $65 per outpatient visit, $202 per ED visit,
and $3971.41 per hospitalization related to diabetes. The cost
for diabetes-related drugs and supplies equaled nearly $7 million
amounting to $512 per recipient. A majority of the prescription
claims were for insulin (34%), thiazolidinediones (25%), oral
sulfonylureas (24%), and home testing supplies (11%). 
CONCLUSION: Utilization for diabetes-related medical services
among a group of recipients covered by Medicaid varied by age,
gender, and ethnicity. Outpatient care and prescription medica-
tions accounted for the most utilized health care resources 
for diabetes.
